If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...

LOUISVILLE, Ky. (WDRB) -- A new alternative designed to provide a solution for cell phone bans in the classroom, as well as student attendance and behavioral monitoring, was unveiled in Louisville on ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

US President Donald Trump believes that America doesn't have enough talented people - yet he is cracking down on immigrat.

A new regulatory pathway for personalised therapies based on 'plausible mechanism', which could see therapies authorised after testing on a tiny number of patients, has been revealed by the FDA. FDA ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...